Hosted by Unknown Host · 🇺🇸 US · PT-BR · 76 episodes
Established thought leaders with verified media credentials.
Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA
Unknown Host hosts TMO EPM / Hemato H9J, a health show with 76 episodes published.
Discussão do artigo: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial" de Platzbecker U, JCO 2025 Apresentado po
Discussão do artigo: "Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" de Woyach J JCO 2025 Apresentado por: Dr. Rafael Faust Discussão po
Discussão do artigo: "Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia" de Al-Sawaf O NEJM 2025 Apresentado por: Dr. Ana Cecilia Bahia Discussão por: Dr. Lais Vianna, Dr. Matheus Garcia, Dr. Lu
Discussão do artigo: "Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation" de Malki M JCO 2025 Apresentado por: Dr Guil
Discussão do artigo: "Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma" de Terpos E Blood 2025 Apresentado por: Dra. Lais Vianna Discussão por: Dr. E
Discussão do artigo: "Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial" de Falchi L
Discussão do artigo: "Intermediate-Dose Cytarabine as Postinduction AML Therapy" de Hunault M NEJM evidence 2025 Apresentado por: Dr. Guilherme Rodrigues Discussão por: Dra. Gabrielle Ritter, Dr. Lucas Salviano, Dr. Rafa
Discussão do artigo: "Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials" de Verstovsek S Blood Adv 2023 Apresentado por: Dra. Ilana Barcessat Discussã
Discussão do artigo: "Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" de Kantarjian H JCO 2024 Apresentado por: Dr. Matheus Garcia D
Discussão do artigo: "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma" de Jagannath S JCO 2025 Apresentado por:
Discussão do artigo: "Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study" de Chavez J blood 2025 Apresentado por: Dra. Ilana Barcessat Discussão por
Discussão do artigo: "Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma" de Wang M JCO 2025 Apresentado por: Dra. Ana Cecilia Bahia Discussão por: Dr. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pe
Discussão do artigo: "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin" de Curtis DJ NEJM 2025 Apresentado por: Dr. Matheus Garcia Discussão por: Dr. Gabrielle Ritter, Dra. Lais Vianna, Dr. Wal
Discussão do artigo: "Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT" de DeFilipp Blood 2025 Apresentado por: Dra. Amanda Chucre Discussão por: Dr. Eduardo Burlamaqui
Discussão do artigo: "Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation" de Yao H JCO 2025 Apresentado por: Dra. Ana Cecilia B
Discussão do artigo: "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study" de Zeiser R JCO 2025 Aprese
Discussão do artigo: "Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826" de Rutherford S JCO 2025 Apresentado por: Dra. Ilana Barcessat Discussã
Discussão do artigo: "Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation" de Hyder M Blood Adv 2025 Apresentado por: Dra. Amanda Chucre Discussão por:
Discussão do artigo: "Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo controlled, phase 3 study" de Wang M Lancet Oncology 2025 Apres
Discussão do artigo: "A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults" de Khandelwal P Blood 2024 Apresentado por: Dra. Lais Vianna Discussão por: Dra. Gabriele Rit
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
TMO EPM / Hemato H9J has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
TMO EPM / Hemato H9J is hosted by Unknown Host. The show is categorised under health (fitness) and has published 76 episodes.
TMO EPM / Hemato H9J has published 76 episodes.
TMO EPM / Hemato H9J regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
TMO EPM / Hemato H9J is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
TMO EPM / Hemato H9J hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of TMO EPM / Hemato H9J average 31 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates TMO EPM / Hemato H9J's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 11 days ago.
